Erenumab
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Erenumab
Erenumab: Known uses and market status in Canada
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Erenumab. Every candidate that can be traced to a source is already a known use, so there is currently no new predicted indication. The one known use is related to an approved indication through the same disease category.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| migraine with brainstem aura | migraine |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02487306 | AIMOVIG | Valid | |
| 02479613 | AIMOVIG | Valid |
Safety Considerations
- Vascular risk: Aura and brainstem symptoms can overlap with ischemic events. The available hemodynamic and vascular-risk studies in general migraine populations are reassuring, but they do not cover brainstem aura specifically.
- Drug interactions: The only interaction on record is pharmacological. Erenumab acts on its target, the CGRP receptor. No drug–drug interactions were identified.
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.